Epidiolex
E275978
Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Epidiolex canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T2523475 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Epidiolex Context triple: [CBD, approvedDrugForm, Epidiolex]
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
C.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Epidiolex Target entity description: Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
C.
Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
antiepileptic drug
ⓘ
cannabidiol-based medication ⓘ pharmaceutical drug ⓘ |
| ageGroupIndication |
adult patients
ⓘ
pediatric patients ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| ATCCode | N03AX24 ⓘ |
| blackBoxWarning | risk of suicidal thoughts and behavior similar to other antiepileptic drugs ⓘ |
| canCause | liver injury ⓘ |
| commonAdverseEffect |
decreased appetite
ⓘ
diarrhea ⓘ elevated liver enzymes ⓘ fatigue ⓘ somnolence ⓘ |
| contains | plant-derived cannabidiol ⓘ |
| controlledSubstanceStatusInUnitedStates | not controlled under the Controlled Substances Act ⓘ |
| developedBy | GW Pharmaceuticals ⓘ |
| doesNotContain | tetrahydrocannabinol ⓘ |
| dosageForm | oral solution ⓘ |
| drugInteractionWith |
CYP2C19 substrates
ⓘ
CYP3A4 substrates ⓘ clobazam ⓘ valproate ⓘ |
| EMAAuthorizationYear | 2019 ⓘ |
| FDAApprovalYear | 2018 ⓘ |
| halfLife | approximately 56 to 61 hours ⓘ |
| hasActiveIngredient | cannabidiol ⓘ |
| indicatedFor |
Dravet syndrome
ⓘ
Lennox-Gastaut syndrome ⓘ tuberous sclerosis complex-associated seizures ⓘ |
| isFirst | FDA-approved drug derived from cannabis ⓘ |
| legalStatusInEuropeanUnion | prescription-only medicine ⓘ |
| legalStatusInUnitedStates | prescription-only medicine ⓘ |
| marketedBy | Jazz Pharmaceuticals ⓘ |
| mechanismOfAction | modulation of endocannabinoid system ⓘ |
| metabolism | hepatic ⓘ |
| metabolizedBy |
CYP2C19
ⓘ
CYP3A4 ⓘ |
| pregnancyCategory | data limited; use only if potential benefit justifies potential risk ⓘ |
| proteinBinding | high ⓘ |
| requiresMonitoring | liver function tests ⓘ |
| routeOfAdministration | oral ⓘ |
| scheduleStatusHistoryInUnitedStates | previously Schedule V controlled substance ⓘ |
| therapeuticArea |
epileptology
ⓘ
neurology ⓘ |
| usedFor |
treatment of rare forms of epilepsy
ⓘ
treatment of seizures ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Epidiolex Description of subject: Epidiolex is a prescription cannabidiol-based medication used to treat certain rare and severe forms of epilepsy.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.